Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors

[1]  J. Soria,et al.  Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors , 2017, BMC Cancer.

[2]  P. Hegde,et al.  Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer , 2017, The oncologist.

[3]  A. D. de Crespigny,et al.  Clinical translation of ferumoxytol‐based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population , 2017, Magnetic resonance in medicine.

[4]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[5]  Weilan Ye,et al.  The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic. , 2016, Developmental cell.

[6]  A. Crow,et al.  MAP4K4 regulates integrin-FERM binding to control endothelial cell motility , 2015, Nature.

[7]  J. Berlin,et al.  A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[8]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[9]  Matthew J. Brauer,et al.  Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies , 2013, Clinical Cancer Research.

[10]  S. Kaye,et al.  Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience , 2012, Clinical Cancer Research.

[11]  A. Jackson,et al.  Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies , 2012, Nature Reviews Clinical Oncology.

[12]  C. Ng,et al.  Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. , 2010, AJR. American journal of roentgenology.

[13]  Helen X. Chen,et al.  A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors , 2009, Clinical Cancer Research.

[14]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[15]  A. Tolcher,et al.  Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study , 2008, Clinical Cancer Research.

[16]  L. Reynolds,et al.  Integrins: the keys to unlocking angiogenesis. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[17]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[18]  A. Joussen,et al.  The role of integrin α5β1 in the regulation of corneal neovascularization , 2007 .

[19]  N. Boudreau,et al.  The Homeobox Transcription Factor Hox D3 Promotes Integrin α5β1 Expression and Function during Angiogenesis* , 2004, Journal of Biological Chemistry.

[20]  Semi Kim,et al.  Inhibition of endothelial cell survival and angiogenesis by protein kinase A. , 2002, The Journal of clinical investigation.

[21]  R. Hynes.  A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.

[22]  D. Taverna,et al.  Reduced blood vessel formation and tumor growth in alpha5-integrin-negative teratocarcinomas and embryoid bodies. , 2001, Cancer research.

[23]  Semi Kim,et al.  Regulation of Angiogenesis in Vivo by Ligation of Integrin α5β1 with the Central Cell-Binding Domain of Fibronectin , 2000 .

[24]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[25]  A. Joussen,et al.  The role of integrin alpha5beta1 in the regulation of corneal neovascularization. , 2007, Experimental eye research.

[26]  S. Mousa,et al.  Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. , 2000, The American journal of pathology.